➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
McKesson
Boehringer Ingelheim
Moodys
AstraZeneca

Last Updated: July 28, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,592,208


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,592,208 protect, and when does it expire?

Patent 9,592,208 protects GILENYA and is included in one NDA.

Protection for GILENYA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-three patent family members in thirty-seven countries.

Summary for Patent: 9,592,208
Title:Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
Abstract: A solid pharmaceutical composition suitable for oral administration, comprising: (a) a S1P receptor modulator; (b) a filler, and (c) a cyclodextrin.
Inventor(s): Rane; Supriya (Parsippany, NJ)
Assignee: Novartis AG (Basel, CH)
Application Number:14/009,241
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Dosage form;

Drugs Protected by US Patent 9,592,208

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis GILENYA fingolimod hydrochloride CAPSULE;ORAL 022527-002 May 11, 2018 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,592,208

PCT Information
PCT FiledMarch 30, 2012PCT Application Number:PCT/US2012/031340
PCT Publication Date:October 04, 2012PCT Publication Number: WO2012/135561

International Family Members for US Patent 9,592,208

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 085749 ⤷  Free Forever Trial
Australia 2012236357 ⤷  Free Forever Trial
Brazil 112013024430 ⤷  Free Forever Trial
Canada 2831600 ⤷  Free Forever Trial
Chile 2013002810 ⤷  Free Forever Trial
China 103476400 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Harvard Business School
Moodys
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.